Abstract:To evaluate completion rate and acute treatment-related toxicity of concurrent chemoradiotherapy with cisplatin 40 mg/m2 for one day per week compared to cisplatin 20 mg/m2 for consecutive five days every three weeks in postoperative radiotherapy for cervical cancer. This retrospective study included 59 patients, with postoperative pathology suggesting cervical malignant tumors, FIGO stage IB-IIA, undergoing radiotherapy and concurrent chemotherapy between January 2013 and December 2017. All patients were divided into two groups, weekly group and triweekly group. Patients of weekly group received weekly cisplatin at a dose of 40 mg/m2 for at least 4 to 5 cycles and patients of triweekly group received 20 mg/m2 cisplatin for five days every three weeks for at least 1 or 2 cycles. All patients received concurrent chemotherapy at the beginning of radiotherapy. Main outcome measures included clinical completion rate and acute treatment-related toxicity. The proportion of patients who completed 4 or 5 cycles chemotherapy in weekly group was 66.7%(20/30), and that completed 1 or 2 cycles chemotherapy in triweekly group was 100%(29/29, P<0.05). Grade 1-2 acute hematological toxicities were similar in the two groups, as follows: grade 1-2 leukopenia (66.7% vs. 51.7%, p>0.05), grade 1-2 thrombocytopenia (10% and 13.7%, p>0.05), and grade 1-2 anemia (43.3% and 20.6%, p>0.05). Most patients in weekly group have no significant gastrointestinal toxicity, while, in triweekly group, 65.5% patients have grade 1-2 nausea or vomiting( p<0.05), with no grade 3-4 gastrointestinal toxicity. Only 3.3% of weekly group were found having grade 1 hepatotoxicity, and only 3.4% of triweekly group were found having grade 1 nephrotoxicity. No treatment related deaths were encountered. This retrospective study appears to show concurrent chemoradiotherapy with triweekly 20mg/m2 cisplatin for consecutive five days in post-operation cervical cancer gives better completion rate with similar Grade 1-2 acute hematological toxicities, hepatotoxicity, and nephrotoxicity. In addition, the main reason that part of patients in triweekly group did not complete the whole chemotherapy courses was hematological toxicities after the first cycle chemotherapy. Nevertheless, the cumulative hematological toxicity of weekly cisplatin 40 mg/m2 was not lower than that of three weekly 20 mg/m2 because of the high frequency of chemotherapy. Due to the reduction of the frequency of chemotherapy, the time of hospitalization and the simplification of hospitalization procedures, the better compliance, and quality of life of three weekly patients are in line with the situation of the shortage of medical resources in China. We will continue to follow up these patients to assess late treatment related toxicity and long term treatment outcomes.

A Multicenter Randomized Phase III Trial to Compare Weekly Usage with Triweekly Usage of Docetaxel and Cisplatin in Concurrent Chemo-radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer.

[A Randomized Phase I/II Trial to Compare Weekly Usage with Triple Weekly Usage of Paclitaxel in Concurrent Radiochemotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer].

[Weekly Paclitaxel and Carboplatin with Concurrent Three Dimensional Conformal Radiotherapy for Locally Advanced Non Small Cell Lung Cancer].

A Study of Weekly Docetaxel and Carboplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer.

Concurrent Chemoradiotherapy with 3-Weekly Versus Weekly Cisplatin in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3 Multicentre Randomised Controlled Trial (Chictr-Trc-12001979).

Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer

P2.02-040 Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer: Topic: Multimodality Treatment

Comparative study between weekly and triweekly paclitaxel and cisplatin regimen in concurrent chemoradiotherapy for cervical squamous cell cancer

Triweekly Versus Weekly Cisplatin Concurrent with Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma

[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].

Etoposide and Cisplatin Versus Paclitaxel and Carboplatin with Concurrent Thoracic Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: a Multicenter Randomized Phase III Trial

Research of three-dimensional conformal radiotherapy combined with concurrent weekly oxaliplatin for inoperable stage Ⅲ non-small cell lung cancer

Multinational Randomized Phase Iii Trial With Or Without Consolidation Chemotherapy Using Docetaxel And Cisplatin After Concurrent Chemoradiation In Inoperable Stage Iii Non-Small-Cell Lung Cancer: Kcsg-Lu05-04

A Comparison of Weekly Versus 3-Weekly Cisplatin During Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma Using Intensity Modulated Radiation Therapy: a Matched Study.

Concurrent chemoradiotherapy for stage Ⅲ non-small cell lung cancer

[Initial Outcome of Induction Chemotherapy with Weekly Paclitaxel Followed by Three-Dimensional Conformal Radiotherapy and Concurrent Weekly Paclitaxel for Stage III Non-Small Cell Lung Cancer].

Concomitant Chemoradiotherapy Using Docetaxel and Cisplatin for Unresectable Stage Iii Lung Squamous Cell Carcinoma

A Study of Concurrent Chemoradiotherapy with Weekly Docetaxel and Cisplatin for Advanced Esophageal Squamous Cell Carcinoma with T4 And/or M1 Lymph Node Metastasis or Locoregional Recurrence

[Concurrent Chemoradiotherapy Followed by Consolidation Chemotherapy and Sequential Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer: Comparison in 93 Patients].

Weekly versus triweekly cisplatin treatment in patients with locally advanced nasopharyngeal cancer during concurrent chemoradiotherapy

Three Weekly Versus Weekly Cisplatin Concurrent Radiotherapy in Patients with Post-operation Cervical Cancer: A Retrospective Analysis